Amgen Inc. (AMGN)
Amgen Inc.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
Amgen reads as neutral right now, with no clear lean either way.
- What's working
- Its price has held up well, trading above its recent averages.
- Worth watching
- It carries more debt, or less cash, than most other healthcare companies.
Analyst price target
~12-month · 29 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide…
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 31,500
- Headquarters
- Thousand Oaks, CA
Similar stocks
What’s behind the score
Valuation
P/E 26.9 — lower than 61% of Healthcare peers
P/B 20.0 — lower than 7% of Healthcare peers
P/S 6.1 — lower than 37% of Healthcare peers
EV/EBITDA 16.0 — lower than 40% of Healthcare peers
EV/Revenue 7.3 — lower than 23% of Healthcare peers
PEG 2.6 — lower than 11% of Healthcare peers
FCF yield 3.7% — higher than 45% of Healthcare peers
Profitability & quality
Gross margin 71.9% — higher than 77% of Healthcare peers
Operating margin 35.5% — higher than 90% of Healthcare peers
Net margin 23.0% — higher than 83% of Healthcare peers
ROE 91.5% — higher than 96% of Healthcare peers
ROA 8.7% — higher than 66% of Healthcare peers
Free cash flow is 99% of reported net income
Financial health
Debt/equity 4.9 — lower than 0% of Healthcare peers
Current ratio 1.37 — higher than 45% of Healthcare peers
Quick ratio 0.95 — higher than 55% of Healthcare peers
Cash/debt 0.24 — higher than 62% of Healthcare peers
Debt/EBITDA 3.32 — lower than 17% of Healthcare peers
Growth
Revenue growth 9.5% YoY — higher than 57% of Healthcare peers
Earnings growth 64.9% YoY — higher than 85% of Healthcare peers
Ownership & investor activity
Payout ratio 60.9% — somewhat unusual vs Healthcare peers
Net insider buying, +3.2% of insider shares
Institutions net sold, -12.1% of shares held
Insiders hold 0.2% of shares outstanding
2.6% of float sold short
Momentum
Above its 50- & 200-day averages
91% of the way from its 52-week low to high